These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24745701)

  • 1. Objective approach for fending off the sublingual immunotherapy placebo effect in subjects with pollenosis: double-blinded, placebo-controlled trial.
    Kralimarkova TZ; Popov TA; Staevska M; Mincheva R; Lazarova C; Racheva R; Mustakov TB; Filipova V; Koleva M; Bacheva K; Dimitrov VD
    Ann Allergy Asthma Immunol; 2014 Jul; 113(1):108-13. PubMed ID: 24745701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.
    Stelmach I; Kaluzińska-Parzyszek I; Jerzynska J; Stelmach P; Stelmach W; Majak P
    Allergy; 2012 Mar; 67(3):312-20. PubMed ID: 22142341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of a short ragweed sublingual immunotherapy tablet.
    Nolte H; Amar N; Bernstein DI; Lanier BQ; Creticos P; Berman G; Kaur A; Hébert J; Maloney J
    Ann Allergy Asthma Immunol; 2014 Jul; 113(1):93-100.e3. PubMed ID: 24836393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study.
    Feliziani V; Lattuada G; Parmiani S; Dall'Aglio PP
    Allergol Immunopathol (Madr); 1995; 23(5):224-30. PubMed ID: 8526180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a randomized controlled trial.
    Mösges R; Brüning H; Hessler HJ; Götz G; Knaussmann HG
    Acta Dermatovenerol Alp Pannonica Adriat; 2007 Dec; 16(4):143-8. PubMed ID: 18204744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
    Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
    Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.
    Howarth P; Malling HJ; Molimard M; Devillier P
    Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
    Serrano E; Wahn HU; Didier A; Bachert C
    Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.